12 / 42
CheckMate 026: Nivolumab vs Chemotherapy in First-line NSCLC
12
PFS and OS (≥5% PD-L1+)
Median OS,
months
14.4
Nivo
13.2
Chemo
Median PFS
4.2
Nivo
5.9
Chemo
Months
OS (%)
24
21
18
15
12
9
6
3
30
100
80
60
40
0
20
0
27
Nivolu
mab
Chemothe
rapy
HR = 1.02
Nivolumab is not better than chemotherapy in 1st line treatment of patients
with PDL1 >/= 5%
Also not better among those with PDL1 >/= 50%
Socinski et al ESMO 2016